Treatment of advanced and recurrent gynecologic cancer

L. W. Brady, Arnold Markoe, T. DeEulis, G. C. Lewis

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In 1986 73,400 new cases of invasive gynecologic cancer and 45,000 new cases of in situ carcinoma of the uterine cervix (about 9% of all cancers in women) were diagnosed in the US. A significant proportion of these patients die of local failure. In dealing with the wide variety of gynecologic cancers, extreme care must be used in choosing the appropriate treatment program for each problem. Therefore, the full extent of the disease at the time of initial presentation and recurrence must be determined. It is only with these data that appropriate treatment programs can be designed with the maximum potential for long-term control or cure and with the minimum in treatment complication. There are no groups of disease processes like those seen in advanced or recurrent gynecologic cancer that offer such a challenge to the clinical practitioner.

Original languageEnglish
Pages (from-to)2081-2093
Number of pages13
JournalCancer
Volume60
Issue number8 SUPPl.
StatePublished - Jan 1 1987
Externally publishedYes

Fingerprint

Neoplasms
Group Processes
Carcinoma in Situ
Therapeutics
Cervix Uteri
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Brady, L. W., Markoe, A., DeEulis, T., & Lewis, G. C. (1987). Treatment of advanced and recurrent gynecologic cancer. Cancer, 60(8 SUPPl.), 2081-2093.

Treatment of advanced and recurrent gynecologic cancer. / Brady, L. W.; Markoe, Arnold; DeEulis, T.; Lewis, G. C.

In: Cancer, Vol. 60, No. 8 SUPPl., 01.01.1987, p. 2081-2093.

Research output: Contribution to journalArticle

Brady, LW, Markoe, A, DeEulis, T & Lewis, GC 1987, 'Treatment of advanced and recurrent gynecologic cancer', Cancer, vol. 60, no. 8 SUPPl., pp. 2081-2093.
Brady LW, Markoe A, DeEulis T, Lewis GC. Treatment of advanced and recurrent gynecologic cancer. Cancer. 1987 Jan 1;60(8 SUPPl.):2081-2093.
Brady, L. W. ; Markoe, Arnold ; DeEulis, T. ; Lewis, G. C. / Treatment of advanced and recurrent gynecologic cancer. In: Cancer. 1987 ; Vol. 60, No. 8 SUPPl. pp. 2081-2093.
@article{9189b6c96c8a4295bd9da82674d6cd14,
title = "Treatment of advanced and recurrent gynecologic cancer",
abstract = "In 1986 73,400 new cases of invasive gynecologic cancer and 45,000 new cases of in situ carcinoma of the uterine cervix (about 9{\%} of all cancers in women) were diagnosed in the US. A significant proportion of these patients die of local failure. In dealing with the wide variety of gynecologic cancers, extreme care must be used in choosing the appropriate treatment program for each problem. Therefore, the full extent of the disease at the time of initial presentation and recurrence must be determined. It is only with these data that appropriate treatment programs can be designed with the maximum potential for long-term control or cure and with the minimum in treatment complication. There are no groups of disease processes like those seen in advanced or recurrent gynecologic cancer that offer such a challenge to the clinical practitioner.",
author = "Brady, {L. W.} and Arnold Markoe and T. DeEulis and Lewis, {G. C.}",
year = "1987",
month = "1",
day = "1",
language = "English",
volume = "60",
pages = "2081--2093",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8 SUPPl.",

}

TY - JOUR

T1 - Treatment of advanced and recurrent gynecologic cancer

AU - Brady, L. W.

AU - Markoe, Arnold

AU - DeEulis, T.

AU - Lewis, G. C.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - In 1986 73,400 new cases of invasive gynecologic cancer and 45,000 new cases of in situ carcinoma of the uterine cervix (about 9% of all cancers in women) were diagnosed in the US. A significant proportion of these patients die of local failure. In dealing with the wide variety of gynecologic cancers, extreme care must be used in choosing the appropriate treatment program for each problem. Therefore, the full extent of the disease at the time of initial presentation and recurrence must be determined. It is only with these data that appropriate treatment programs can be designed with the maximum potential for long-term control or cure and with the minimum in treatment complication. There are no groups of disease processes like those seen in advanced or recurrent gynecologic cancer that offer such a challenge to the clinical practitioner.

AB - In 1986 73,400 new cases of invasive gynecologic cancer and 45,000 new cases of in situ carcinoma of the uterine cervix (about 9% of all cancers in women) were diagnosed in the US. A significant proportion of these patients die of local failure. In dealing with the wide variety of gynecologic cancers, extreme care must be used in choosing the appropriate treatment program for each problem. Therefore, the full extent of the disease at the time of initial presentation and recurrence must be determined. It is only with these data that appropriate treatment programs can be designed with the maximum potential for long-term control or cure and with the minimum in treatment complication. There are no groups of disease processes like those seen in advanced or recurrent gynecologic cancer that offer such a challenge to the clinical practitioner.

UR - http://www.scopus.com/inward/record.url?scp=0023231682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023231682&partnerID=8YFLogxK

M3 - Article

C2 - 3308068

AN - SCOPUS:0023231682

VL - 60

SP - 2081

EP - 2093

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8 SUPPl.

ER -